Beyond their prognostic impact, the RAS/RAF/MEK/ERK pathway alterations appear implicated in the mechanisms of sensitivity and resistance to a vast array of drugs, with relevance for all breast cancer subtypes. The gene discussed is MAPK1; the disease is breast cancer.